Anti-angiogenic therapies aim to inhibit the formation of new blood vessels in tumors, thereby starving the tumor of essential nutrients and oxygen. Bevacizumab (Avastin) is a well-known anti-angiogenic drug that targets VEGF. By blocking VEGF, bevacizumab prevents the binding of this growth factor to its receptors on endothelial cells, thus inhibiting angiogenesis.